CORONA vs VIVIMEDLAB: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 10; VIVIMEDLAB leads 0 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CORONA | VIVIMEDLAB |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | CORONA | VIVIMEDLAB |
|---|---|---|
| Live Price | ₹2,010 | ₹7.39 |
| Day Change | 0.3% | -3.15% |
| Volume | 17,444 | 1.47 L |
| 52-Week High | ₹2,292.4 | ₹20.59 |
| 52-Week Low | ₹1,336.6 | ₹5.15 |
| Distance from 52W High | -12.32% | -64.11% |
Valuation
| Metric | CORONA | VIVIMEDLAB |
|---|---|---|
| Market Cap | ₹12,313 Cr | ₹53 Cr |
| P/E Ratio | 61.87x | — |
| P/B Ratio | 16.49x | — |
| EPS | ₹9.83 | ₹-17.61 |
| Book Value | ₹122.12 | — |
| Dividend Yield | 0.5% | 0% |
Growth
| Metric | CORONA | VIVIMEDLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -22.42% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | -24.95% |
| Qtr Profit Growth | 0% | -782.17% |
Profitability & Leverage
| Metric | CORONA | VIVIMEDLAB |
|---|---|---|
| ROE | 24.28% | -57.01% |
| ROCE | 20.94% | -5.3% |
| Net Margin | 13.19% | -27.09% |
| Operating Margin | 15.89% | -40.67% |
| Debt to Equity | 0.19x | 8.29x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CORONA | VIVIMEDLAB |
|---|---|---|
| Promoter Holding | 69% | 7.57%▼ 0.2 pp |
| FII Holding | 4.21%▲ 0.58 pp | 1.64% |
| DII Holding | 16.45%▲ 3.55 pp | 0% |
| Public Holding | 10.34%▼ 4.14 pp | 90.67%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and VIVIMEDLAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.